TD Asset Management Inc trimmed its holdings in Nevro Corp. (NYSE:NVRO – Get Rating) by 53.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,290 shares of the medical equipment provider’s stock after selling 18,650 shares during the quarter. TD Asset Management Inc’s holdings in Nevro were worth $645,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Assetmark Inc. boosted its stake in shares of Nevro by 63.4% during the 3rd quarter. Assetmark Inc. now owns 930 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 361 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Nevro during the 3rd quarter worth about $54,000. Barclays PLC boosted its stake in shares of Nevro by 43.5% during the 3rd quarter. Barclays PLC now owns 2,864 shares of the medical equipment provider’s stock worth $134,000 after acquiring an additional 868 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Nevro during the 1st quarter worth about $170,000. Finally, Prelude Capital Management LLC purchased a new stake in shares of Nevro during the 3rd quarter worth about $202,000. 96.03% of the stock is owned by hedge funds and other institutional investors.
Nevro Stock Down 3.0 %
Shares of NYSE NVRO opened at $27.11 on Friday. The company has a 50 day simple moving average of $32.43 and a 200-day simple moving average of $37.00. The company has a market capitalization of $971.00 million, a P/E ratio of -2,711.00 and a beta of 0.86. The company has a debt-to-equity ratio of 0.62, a current ratio of 7.15 and a quick ratio of 5.63. Nevro Corp. has a 1 year low of $26.40 and a 1 year high of $53.34.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. Mizuho began coverage on shares of Nevro in a research note on Thursday, April 13th. They set a “neutral” rating and a $40.00 target price on the stock. Piper Sandler reduced their price target on shares of Nevro from $37.00 to $34.00 in a research report on Thursday, April 27th. Citigroup downgraded shares of Nevro from a “buy” rating to a “neutral” rating and set a $40.00 price target for the company. in a research report on Tuesday, January 17th. Truist Financial reduced their price target on shares of Nevro from $42.00 to $40.00 and set a “hold” rating for the company in a research report on Monday, April 17th. Finally, Canaccord Genuity Group upped their price target on shares of Nevro from $67.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, February 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Nevro currently has an average rating of “Hold” and a consensus price target of $47.50.
Nevro Company Profile
Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
- Get a free copy of the StockNews.com research report on Nevro (NVRO)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVRO – Get Rating).
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.